• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Fractyl raises $100M for diabetes reversal tech, renamed as Fractyl Health

June 16, 2021 By Sean Whooley

Fractyl-Logo-CMYK-June2021-02Fractyl Labs today announced the closing of a $100 million Series F financing round in addition to a name change to Fractyl Health.

Lexington, Mass.-based Fractyl Health received contributions to the round from new investors Maverick Capital, M28 Capital and Population Health Partners, while other new and existing investors participated, too.

According to a news release, M28 Capital founder Marc Elia and Population Health Partners executive chairman and founder Dr. Clive Meanwell joined Fractyl’s board of directors as a result.

“We’re immensely proud of the leadership role Fractyl has established in creating innovative treatments to address the root cause of metabolic disease, with an initial focus on type 2 diabetes. The closing of this Series F financing, the significant experience of our new board members, and our company’s renaming as Fractyl Health reflect the momentum we have built and the vast potential that lies ahead for our approach,” Fractyl co-founder & CEO Dr. Harith Rajagopalan said in the release. “By controlling the body’s central metabolic control organ, the duodenum, we believe we’ve discovered a novel way to treat metabolic disease at its source. This financing will enable the expansion and acceleration of our clinical development efforts with the goal of reducing insulin dependence for patients with type 2 diabetes on a global scale.”

READ: “How Fractyl Labs is ‘reversing’ type 2 diabetes to reduce or eliminate insulin injections” — an interview with co-founder & CEO Harith Rajagopalan.

Fractyl in April garnered FDA breakthrough device designation for its Revita DMR procedure designed to resurface the upper intestine lining (duodenal mucosa) in metabolic disease for patients with insulin-treated type 2 diabetes. Through the procedure, the company aims to minimize or eliminate the need for type 2 diabetes patients to receive insulin treatment.

The company has begun enrolling patients in the Revita-T2Di study that will evaluate the procedure. Fractyl also recently confirmed that CMS approved coverage of routine costs for Medicare patients in the Revita-T2Di trial, with all eligible participants set to receive study-related health assessments at no cost. The decision allows for reimbursement coverage to clinical research centers for certain trial-related expenses.

“Fractyl is developing technology that stands apart from the rest of the landscape in metabolic therapeutic innovation. Patients with diabetes — and our broader society — desperately need a therapy that offers disease modification as well as relief from the clinical, practical, and financial burden inherent in the current metabolic standard of care,” Elia said. “Eliminating the need for insulin therapy from type 2 diabetes would be a landmark achievement for patients and society. I look forward to helping Fractyl as it works toward its mission.”

Filed Under: Business/Financial News, Clinical Trials, Diabetes, Featured, Funding Roundup Tagged With: Fractyl Health, fractyllaboratories

IN CASE YOU MISSED IT

  • BD files patent infringement lawsuit against Baxter over infusion pump tech
  • Tandem Diabetes Care subsidiary earns new FDA clearance for insulin infusion set
  • Glucotrack can proceed with long-term glucose monitor study in Australia
  • Dexcom promotes Jake Leach to president role
  • Roche invests $550M to make Indianapolis a CGM manufacturing hub

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS